Skip to main content Skip to footer
HomeHome
 
  • Homepage
  • Searching for patents

    Patent knowledge

    Access our patent databases and search tools.

    Go to overview 

    • Overview
    • Technical information
      • Overview
      • Espacenet - patent search
      • European Publication Server
      • EP full-text search
    • Legal information
      • Overview
      • European Patent Register
      • European Patent Bulletin
      • European Case Law Identifier sitemap
      • Third-party observations
    • Business information
      • Overview
      • PATSTAT
      • IPscore
      • Technology insight reports
    • Data
      • Overview
      • Technology Intelligence Platform
      • Linked open EP data
      • Bulk data sets
      • Web services
      • Coverage, codes and statistics
    • Technology platforms
      • Overview
      • Plastics in transition
      • Water innovation
      • Space innovation
      • Technologies combatting cancer
      • Firefighting technologies
      • Clean energy technologies
      • Fighting coronavirus
    • Helpful resources
      • Overview
      • First time here?
      • Asian patent information
      • Patent information centres
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge
    Image
    Plastics in Transition

    Technology insight report on plastic waste management

  • Applying for a patent

    Applying for a patent

    Practical information on filing and grant procedures.

    Go to overview 

    • Overview
    • European route
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
      • Appeals
      • Unitary Patent & Unified Patent Court
      • National validation
      • Request for extension/validation
    • International route (PCT)
      • Overview
      • Euro-PCT Guide – PCT procedure at the EPO
      • EPO decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
      • Training and events
    • National route
    • Find a professional representative
    • MyEPO services
      • Overview
      • Understand our services
      • Get access
      • File with us
      • Interact with us on your files
      • Online Filing & fee payment outages
    • Forms
      • Overview
      • Request for examination
    • Fees
      • Overview
      • European fees (EPC)
      • International fees (PCT)
      • Unitary Patent fees (UP)
      • Fee payment and refunds
      • Warning

    UP

    Find out how the Unitary Patent can enhance your IP strategy

  • Law & practice

    Law & practice

    European patent law, the Official Journal and other legal texts.

    Go to overview 

    • Overview
    • Legal texts
      • Overview
      • European Patent Convention
      • Official Journal
      • Guidelines
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
      • Unitary patent system
      • National measures relating to the Unitary Patent
    • Court practices
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives
    Image
    Law and practice scales 720x237

    Keep up with key aspects of selected BoA decisions with our monthly "Abstracts of decisions”

  • News & events

    News & events

    Our latest news, podcasts and events, including the European Inventor Award.

    Go to overview 

     

    • Overview
    • News
    • Events
    • European Inventor Award
      • Overview
      • The meaning of tomorrow
      • About the award
      • Categories and prizes
      • Meet the finalists
      • Nominations
      • European Inventor Network
      • The 2024 event
    • Young Inventor Prize
      • Overview
      • About the prize
      • Nominations
      • The jury
      • The world, reimagined
    • Press centre
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • Innovation and patenting in focus
      • Overview
      • Water-related technologies
      • CodeFest
      • Green tech in focus
      • Research institutes
      • Women inventors
      • Lifestyle
      • Space and satellites
      • The future of medicine
      • Materials science
      • Mobile communications
      • Biotechnology
      • Patent classification
      • Digital technologies
      • The future of manufacturing
      • Books by EPO experts
    • "Talk innovation" podcast

    Podcast

    From ideas to inventions: tune into our podcast for the latest in tech and IP

  • Learning

    Learning

    The European Patent Academy – the point of access to your learning

    Go to overview 

    • Overview
    • Learning activities and paths
      • Overview
      • Learning activities
      • Learning paths
    • EQE and EPAC
      • Overview
      • EQE - European qualifying examination
      • EPAC - European patent administration certification
      • CSP – Candidate Support Programme
    • Learning resources by area of interest
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
    • Learning resources by profile
      • Overview
      • Business and IP managers
      • EQE and EPAC Candidates
      • Judges, lawyers and prosecutors
      • National offices and IP authorities
      • Patent attorneys and paralegals
      • Universities, research centres and technology transfer centres (TTOs)
    Image
    Patent Academy catalogue

    Have a look at the extensive range of learning opportunities in the European Patent Academy training catalogue

  • About us

    About us

    Find out more about our work, values, history and vision

    Go to overview 

    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Overview
      • Official celebrations
      • Member states’ video statements
      • 50 Leading Tech Voices
      • Athens Marathon
      • Kids’ collaborative art competition
    • Legal foundations and member states
      • Overview
      • Legal foundations
      • Member states of the European Patent Organisation
      • Extension states
      • Validation states
    • Administrative Council and subsidiary bodies
      • Overview
      • Communiqués
      • Calendar
      • Documents and publications
      • Administrative Council
    • Principles & strategy
      • Overview
      • Our mission, vision, values and corporate policy
      • Strategic Plan 2028
      • Towards a New Normal
    • Leadership & management
      • Overview
      • President António Campinos
      • Management Advisory Committee
    • Sustainability at the EPO
      • Overview
      • Environmental
      • Social
      • Governance and Financial sustainability
    • Services & activities
      • Overview
      • Our services & structure
      • Quality
      • Consulting our users
      • European and international co-operation
      • European Patent Academy
      • Chief Economist
      • Ombuds Office
      • Reporting wrongdoing
    • Observatory on Patents and Technology
      • Overview
      • Innovation actors
      • Policy and funding
      • Tools
      • About the Observatory
    • Procurement
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • Sustainable Procurement Policy
      • About eTendering and electronic signatures
      • Procurement portal
      • Invoicing
      • General conditions
      • Archived tenders
    • Transparency portal
      • Overview
      • General
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
    • Statistics and trends
      • Overview
      • Statistics & Trends Centre
      • Patent Index 2024
      • EPO Data Hub
      • Clarification on data sources
    • History
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s
    • Art collection
      • Overview
      • The collection
      • Let's talk about art
      • Artists
      • Media library
      • What's on
      • Publications
      • Contact
      • Culture Space A&T 5-10
      • "Long Night"
    Image
    Patent Index 2024 keyvisual showing brightly lit up data chip, tinted in purple, bright blue

    Track the latest tech trends with our Patent Index

 
en de fr
  • Language selection
  • English
  • Deutsch
  • Français
Main navigation
  • Homepage
    • Go back
    • New to patents
  • New to patents
    • Go back
    • Your business and patents
    • Why do we have patents?
    • What's your big idea?
    • Are you ready?
    • What to expect
    • How to apply for a patent
    • Is it patentable?
    • Are you first?
    • Patent quiz
    • Unitary patent video
  • Searching for patents
    • Go back
    • Overview
    • Technical information
      • Go back
      • Overview
      • Espacenet - patent search
        • Go back
        • Overview
        • National patent office databases
        • Global Patent Index (GPI)
        • Release notes
      • European Publication Server
        • Go back
        • Overview
        • Release notes
        • Cross-reference index for Euro-PCT applications
        • EP authority file
        • Help
      • EP full-text search
    • Legal information
      • Go back
      • Overview
      • European Patent Register
        • Go back
        • Overview
        • Release notes archive
        • Register documentation
          • Go back
          • Overview
          • Deep link data coverage
          • Federated Register
          • Register events
      • European Patent Bulletin
        • Go back
        • Overview
        • Download Bulletin
        • EP Bulletin search
        • Help
      • European Case Law Identifier sitemap
      • Third-party observations
    • Business information
      • Go back
      • Overview
      • PATSTAT
      • IPscore
        • Go back
        • Release notes
      • Technology insight reports
    • Data
      • Go back
      • Overview
      • Technology Intelligence Platform
      • Linked open EP data
      • Bulk data sets
        • Go back
        • Overview
        • Manuals
        • Sequence listings
        • National full-text data
        • European Patent Register data
        • EPO worldwide bibliographic data (DOCDB)
        • EP full-text data
        • EPO worldwide legal event data (INPADOC)
        • EP bibliographic data (EBD)
        • Boards of Appeal decisions
      • Web services
        • Go back
        • Overview
        • Open Patent Services (OPS)
        • European Publication Server web service
      • Coverage, codes and statistics
        • Go back
        • Weekly updates
        • Updated regularly
    • Technology platforms
      • Go back
      • Overview
      • Plastics in transition
        • Go back
        • Overview
        • Plastics waste recovery
        • Plastics waste recycling
        • Alternative plastics
      • Innovation in water technologies
        • Go back
        • Overview
        • Clean water
        • Protection from water
      • Space innovation
        • Go back
        • Overview
        • Cosmonautics
        • Space observation
      • Technologies combatting cancer
        • Go back
        • Overview
        • Prevention and early detection
        • Diagnostics
        • Therapies
        • Wellbeing and aftercare
      • Firefighting technologies
        • Go back
        • Overview
        • Detection and prevention of fires
        • Fire extinguishing
        • Protective equipment
        • Post-fire restoration
      • Clean energy technologies
        • Go back
        • Overview
        • Renewable energy
        • Carbon-intensive industries
        • Energy storage and other enabling technologies
      • Fighting coronavirus
        • Go back
        • Overview
        • Vaccines and therapeutics
          • Go back
          • Overview
          • Vaccines
          • Overview of candidate therapies for COVID-19
          • Candidate antiviral and symptomatic therapeutics
          • Nucleic acids and antibodies to fight coronavirus
        • Diagnostics and analytics
          • Go back
          • Overview
          • Protein and nucleic acid assays
          • Analytical protocols
        • Informatics
          • Go back
          • Overview
          • Bioinformatics
          • Healthcare informatics
        • Technologies for the new normal
          • Go back
          • Overview
          • Devices, materials and equipment
          • Procedures, actions and activities
          • Digital technologies
        • Inventors against coronavirus
    • Helpful resources
      • Go back
      • Overview
      • First time here?
        • Go back
        • Overview
        • Basic definitions
        • Patent classification
          • Go back
          • Overview
          • Cooperative Patent Classification (CPC)
        • Patent families
          • Go back
          • Overview
          • DOCDB simple patent family
          • INPADOC extended patent family
        • Legal event data
          • Go back
          • Overview
          • INPADOC classification scheme
      • Asian patent information
        • Go back
        • Overview
        • China (CN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Chinese Taipei (TW)
          • Go back
          • Overview
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • India (IN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
        • Japan (JP)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Korea (KR)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Russian Federation (RU)
          • Go back
          • Overview
          • Facts and figures
          • Numbering system
          • Searching in databases
        • Useful links
      • Patent information centres (PATLIB)
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge
  • Applying for a patent
    • Go back
    • Overview
    • European route
      • Go back
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
        • Go back
        • Oral proceedings calendar
          • Go back
          • Calendar
          • Public access to appeal proceedings
          • Public access to opposition proceedings
          • Technical guidelines
      • Appeals
      • Unitary Patent & Unified Patent Court
        • Go back
        • Overview
        • Unitary Patent
          • Go back
          • Overview
          • Legal framework
          • Main features
          • Applying for a Unitary Patent
          • Cost of a Unitary Patent
          • Translation and compensation
          • Start date
          • Introductory brochures
        • Unified Patent Court
      • National validation
      • Extension/validation request
    • International route
      • Go back
      • Overview
      • Euro-PCT Guide
      • Entry into the European phase
      • Decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
        • Go back
        • Patent Prosecution Highway (PPH) programme outline
      • Training and events
    • National route
    • MyEPO services
      • Go back
      • Overview
      • Understand our services
        • Go back
        • Overview
        • Exchange data with us using an API
          • Go back
          • Release notes
      • Get access
        • Go back
        • Overview
        • Release notes
      • File with us
        • Go back
        • Overview
        • What if our online filing services are down?
        • Release notes
      • Interact with us on your files
        • Go back
        • Release notes
      • Online Filing & fee payment outages
    • Fees
      • Go back
      • Overview
      • European fees (EPC)
        • Go back
        • Overview
        • Decisions and notices
      • International fees (PCT)
        • Go back
        • Reduction in fees
        • Fees for international applications
        • Decisions and notices
        • Overview
      • Unitary Patent fees (UP)
        • Go back
        • Overview
        • Decisions and notices
      • Fee payment and refunds
        • Go back
        • Overview
        • Payment methods
        • Getting started
        • FAQs and other documentation
        • Technical information for batch payments
        • Decisions and notices
        • Release notes
      • Warning
    • Forms
      • Go back
      • Overview
      • Request for examination
    • Find a professional representative
  • Law & practice
    • Go back
    • Overview
    • Legal texts
      • Go back
      • Overview
      • European Patent Convention
        • Go back
        • Overview
        • Archive
          • Go back
          • Overview
          • Documentation on the EPC revision 2000
            • Go back
            • Overview
            • Diplomatic Conference for the revision of the EPC
            • Travaux préparatoires
            • New text
            • Transitional provisions
            • Implementing regulations to the EPC 2000
            • Rules relating to Fees
            • Ratifications and accessions
          • Travaux Préparatoires EPC 1973
      • Official Journal
      • Guidelines
        • Go back
        • Overview
        • EPC Guidelines
        • PCT-EPO Guidelines
        • Unitary Patent Guidelines
        • Guidelines revision cycle
        • Consultation results
        • Summary of user responses
        • Archive
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
        • Go back
        • Overview
        • Archive
      • Unitary Patent system
        • Go back
        • Travaux préparatoires to UP and UPC
      • National measures relating to the Unitary Patent 
    • Court practices
      • Go back
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Go back
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Go back
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives
  • News & events
    • Go back
    • Overview
    • News
    • Events
    • European Inventor Award
      • Go back
      • Overview
      • The meaning of tomorrow
      • About the award
      • Categories and prizes
      • Meet the inventors
      • Nominations
      • European Inventor Network
        • Go back
        • 2024 activities
        • 2025 activities
        • Rules and criteria
        • FAQ
      • The 2024 event
    • Young Inventors Prize
      • Go back
      • Overview
      • About the prize
      • Nominations
      • The jury
      • The world, reimagined
      • The 2025 event
    • Press centre
      • Go back
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
        • Go back
        • Overview
        • European Patent Office
        • Q&A on patents related to coronavirus
        • Q&A on plant patents
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • In focus
      • Go back
      • Overview
      • Water-related technologies
      • CodeFest
        • Go back
        • CodeFest Spring 2025 on classifying patent data for sustainable development
        • Overview
        • CodeFest 2024 on generative AI
        • CodeFest 2023 on Green Plastics
      • Green tech in focus
        • Go back
        • Overview
        • About green tech
        • Renewable energies
        • Energy transition technologies
        • Building a greener future
      • Research institutes
      • Women inventors
      • Lifestyle
      • Space and satellites
        • Go back
        • Overview
        • Patents and space technologies
      • Healthcare
        • Go back
        • Overview
        • Medical technologies and cancer
        • Personalised medicine
      • Materials science
        • Go back
        • Overview
        • Nanotechnology
      • Mobile communications
      • Biotechnology
        • Go back
        • Overview
        • Red, white or green
        • The role of the EPO
        • What is patentable?
        • Biotech inventors
      • Classification
        • Go back
        • Overview
        • Nanotechnology
        • Climate change mitigation technologies
          • Go back
          • Overview
          • External partners
          • Updates on Y02 and Y04S
      • Digital technologies
        • Go back
        • Overview
        • About ICT
        • Hardware and software
        • Artificial intelligence
        • Fourth Industrial Revolution
      • Additive manufacturing
        • Go back
        • Overview
        • About AM
        • AM innovation
      • Books by EPO experts
    • Podcast
  • Learning
    • Go back
    • Overview
    • Learning activities and paths
      • Go back
      • Overview
      • Learning activities: types and formats
      • Learning paths
    • EQE and EPAC
      • Go back
      • Overview
      • EQE - European Qualifying Examination
        • Go back
        • Overview
        • Compendium
          • Go back
          • Overview
          • Paper F
          • Paper A
          • Paper B
          • Paper C
          • Paper D
          • Pre-examination
        • Candidates successful in the European qualifying examination
        • Archive
      • EPAC - European patent administration certification
      • CSP – Candidate Support Programme
    • Learning resources by area of interest
      • Go back
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
    • Learning resources by profile
      • Go back
      • Overview
      • Business and IP managers
        • Go back
        • Overview
        • Innovation case studies
          • Go back
          • Overview
          • SME case studies
          • Technology transfer case studies
          • High-growth technology case studies
        • Inventor's handbook
          • Go back
          • Overview
          • Introduction
          • Disclosure and confidentiality
          • Novelty and prior art
          • Competition and market potential
          • Assessing the risk ahead
          • Proving the invention
          • Protecting your idea
          • Building a team and seeking funding
          • Business planning
          • Finding and approaching companies
          • Dealing with companies
        • Best of search matters
          • Go back
          • Overview
          • Tools and databases
          • EPO procedures and initiatives
          • Search strategies
          • Challenges and specific topics
        • Support for high-growth technology businesses
          • Go back
          • Overview
          • Business decision-makers
          • IP professionals
          • Stakeholders of the Innovation Ecosystem
      • EQE and EPAC Candidates
        • Go back
        • Overview
        • Paper F brain-teasers
        • Daily D questions
        • European qualifying examination - Guide for preparation
        • EPAC
      • Judges, lawyers and prosecutors
        • Go back
        • Overview
        • Compulsory licensing in Europe
        • The jurisdiction of European courts in patent disputes
      • National offices and IP authorities
        • Go back
        • Overview
        • Learning material for examiners of national officers
        • Learning material for formalities officers and paralegals
      • Patent attorneys and paralegals
      • Universities, research centres and TTOs
        • Go back
        • Overview
        • Modular IP Education Framework (MIPEF)
        • Pan-European Seal Young Professionals Programme
          • Go back
          • Overview
          • For students
          • For universities
            • Go back
            • Overview
            • IP education resources
            • University memberships
          • Our young professionals
          • Professional development plan
        • Academic Research Programme
          • Go back
          • Overview
          • Completed research projects
          • Current research projects
        • IP Teaching Kit
          • Go back
          • Overview
          • Download modules
        • Intellectual property course design manual
        • PATLIB Knowledge Transfer to Africa
          • Go back
          • The PATLIB Knowledge Transfer to Africa initiative (KT2A)
          • KT2A core activities
          • Success story: Malawi University of Science and Technology and PATLIB Birmingham
  • About us
    • Go back
    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Go back
      • Official celebrations
      • Overview
      • Member states’ video statements
        • Go back
        • Albania
        • Austria
        • Belgium
        • Bulgaria
        • Croatia
        • Cyprus
        • Czech Republic
        • Denmark
        • Estonia
        • Finland
        • France
        • Germany
        • Greece
        • Hungary
        • Iceland
        • Ireland
        • Italy
        • Latvia
        • Liechtenstein
        • Lithuania
        • Luxembourg
        • Malta
        • Monaco
        • Montenegro
        • Netherlands
        • North Macedonia
        • Norway
        • Poland
        • Portugal
        • Romania
        • San Marino
        • Serbia
        • Slovakia
        • Slovenia
        • Spain
        • Sweden
        • Switzerland
        • Türkiye
        • United Kingdom
      • 50 Leading Tech Voices
      • Athens Marathon
      • Kids’ collaborative art competition
    • Legal foundations and member states
      • Go back
      • Overview
      • Legal foundations
      • Member states
        • Go back
        • Overview
        • Member states by date of accession
      • Extension states
      • Validation states
    • Administrative Council and subsidiary bodies
      • Go back
      • Overview
      • Communiqués
        • Go back
        • 2024
        • Overview
        • 2023
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
        • 2013
      • Calendar
      • Documents and publications
        • Go back
        • Overview
        • Select Committee documents
      • Administrative Council
        • Go back
        • Overview
        • Composition
        • Representatives
        • Rules of Procedure
        • Board of Auditors
        • Secretariat
        • Council bodies
    • Principles & strategy
      • Go back
      • Overview
      • Mission, vision, values & corporate policy
      • Strategic Plan 2028
        • Go back
        • Driver 1: People
        • Driver 2: Technologies
        • Driver 3: High-quality, timely products and services
        • Driver 4: Partnerships
        • Driver 5: Financial sustainability
      • Towards a New Normal
      • Data protection & privacy notice
    • Leadership & management
      • Go back
      • Overview
      • About the President
      • Management Advisory Committee
    • Sustainability at the EPO
      • Go back
      • Overview
      • Environmental
        • Go back
        • Overview
        • Inspiring environmental inventions
      • Social
        • Go back
        • Overview
        • Inspiring social inventions
      • Governance and Financial sustainability
    • Procurement
      • Go back
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • Dynamic Purchasing System (DPS) publications
      • Sustainable Procurement Policy
      • About eTendering
      • Invoicing
      • Procurement portal
        • Go back
        • Overview
        • e-Signing contracts
      • General conditions
      • Archived tenders
    • Services & activities
      • Go back
      • Overview
      • Our services & structure
      • Quality
        • Go back
        • Overview
        • Foundations
          • Go back
          • Overview
          • European Patent Convention
          • Guidelines for examination
          • Our staff
        • Enabling quality
          • Go back
          • Overview
          • Prior art
          • Classification
          • Tools
          • Processes
        • Products & services
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
          • Continuous improvement
        • Quality through networking
          • Go back
          • Overview
          • User engagement
          • Co-operation
          • User satisfaction survey
          • Stakeholder Quality Assurance Panels
        • Patent Quality Charter
        • Quality Action Plan
        • Quality dashboard
        • Statistics
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
        • Integrated management at the EPO
      • Consulting our users
        • Go back
        • Overview
        • Standing Advisory Committee before the EPO (SACEPO)
          • Go back
          • Overview
          • Objectives
          • SACEPO and its working parties
          • Meetings
          • Single Access Portal – SACEPO Area
        • Surveys
          • Go back
          • Overview
          • Detailed methodology
          • Search services
          • Examination services, final actions and publication
          • Opposition services
          • Formalities services
          • Customer services
          • Filing services
          • Key Account Management (KAM)
          • Website
          • Archive
      • Our user service charter
      • European and international co-operation
        • Go back
        • Overview
        • Co-operation with member states
          • Go back
          • Overview
        • Bilateral co-operation with non-member states
          • Go back
          • Overview
          • Validation system
          • Reinforced Partnership programme
        • Multilateral international co-operation with IP offices and organisations
        • Co-operation with international organisations outside the IP system
      • European Patent Academy
        • Go back
        • Overview
        • Partners
      • Chief Economist
        • Go back
        • Overview
        • Economic studies
      • Ombuds Office
      • Reporting wrongdoing
    • Observatory on Patents and Technology
      • Go back
      • Overview
      • Innovation against cancer
      • Innovation actors
        • Go back
        • Overview
        • Startups and SMEs
      • Policy and funding
        • Go back
        • Overview
        • Financing innovation programme
          • Go back
          • Overview
          • Our studies on the financing of innovation
          • EPO initiatives for patent applicants
          • Financial support for innovators in Europe
        • Patents and standards
          • Go back
          • Overview
          • Publications
          • Patent standards explorer
      • Tools
        • Go back
        • Overview
        • Deep Tech Finder
      • About the Observatory
        • Go back
        • Overview
        • Work plan
    • Transparency portal
      • Go back
      • Overview
      • General
        • Go back
        • Overview
        • Annual Review 2023
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • 50 years of the EPC
          • Strategic key performance indicators
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
        • Annual Review 2022
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
    • Statistics and trends
      • Go back
      • Overview
      • Statistics & Trends Centre
      • Patent Index 2024
        • Go back
        • Insight into computer technology and AI
        • Insight into clean energy technologies
        • Statistics and indicators
          • Go back
          • European patent applications
            • Go back
            • Key trend
            • Origin
            • Top 10 technical fields
              • Go back
              • Computer technology
              • Electrical machinery, apparatus, energy
              • Digital communication
              • Medical technology
              • Transport
              • Measurement
              • Biotechnology
              • Pharmaceuticals
              • Other special machines
              • Organic fine chemistry
            • All technical fields
          • Applicants
            • Go back
            • Top 50
            • Categories
            • Women inventors
          • Granted patents
            • Go back
            • Key trend
            • Origin
            • Designations
      • Data to download
      • EPO Data Hub
      • Clarification on data sources
    • History
      • Go back
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s
    • Art collection
      • Go back
      • Overview
      • The collection
      • Let's talk about art
      • Artists
      • Media library
      • What's on
      • Publications
      • Contact
      • Culture Space A&T 5-10
        • Go back
        • Catalyst lab & Deep vision
          • Go back
          • Irene Sauter (DE)
          • AVPD (DK)
          • Jan Robert Leegte (NL)
          • Jānis Dzirnieks (LV) #1
          • Jānis Dzirnieks (LV) #2
          • Péter Szalay (HU)
          • Thomas Feuerstein (AT)
          • Tom Burr (US)
          • Wolfgang Tillmans (DE)
          • TerraPort
          • Unfinished Sculpture - Captives #1
          • Deep vision – immersive exhibition
          • Previous exhibitions
        • The European Patent Journey
        • Sustaining life. Art in the climate emergency
        • Next generation statements
        • Open storage
        • Cosmic bar
      • "Long Night"
  • Boards of Appeal
    • Go back
    • Overview
    • Decisions of the Boards of Appeal
      • Go back
      • Overview
      • Recent decisions
      • Selected decisions
    • Information from the Boards of Appeal
    • Procedure
    • Oral proceedings
    • About the Boards of Appeal
      • Go back
      • Overview
      • President of the Boards of Appeal
      • Enlarged Board of Appeal
        • Go back
        • Overview
        • Pending referrals (Art. 112 EPC)
        • Decisions sorted by number (Art. 112 EPC)
        • Pending petitions for review (Art. 112a EPC)
        • Decisions on petitions for review (Art. 112a EPC)
      • Technical Boards of Appeal
      • Legal Board of Appeal
      • Disciplinary Board of Appeal
      • Presidium
        • Go back
        • Overview
    • Code of Conduct
    • Business distribution scheme
      • Go back
      • Overview
      • Technical boards of appeal by IPC in 2025
      • Archive
    • Annual list of cases
    • Communications
    • Annual reports
      • Go back
      • Overview
    • Publications
      • Go back
      • Abstracts of decisions
    • Case Law of the Boards of Appeal
      • Go back
      • Overview
      • Archive
  • Service & support
    • Go back
    • Overview
    • Website updates
    • Availability of online services
      • Go back
      • Overview
    • FAQ
      • Go back
      • Overview
    • Publications
    • Ordering
      • Go back
      • Overview
      • Patent Knowledge Products and Services
      • Terms and conditions
        • Go back
        • Overview
        • Patent information products
        • Bulk data sets
        • Open Patent Services (OPS)
        • Fair use charter
    • Procedural communications
    • Useful links
      • Go back
      • Overview
      • Patent offices of member states
      • Other patent offices
      • Directories of patent attorneys
      • Patent databases, registers and gazettes
      • Disclaimer
    • Contact us
      • Go back
      • Overview
      • Filing options
      • Locations
    • Subscription centre
      • Go back
      • Overview
      • Subscribe
      • Change preferences
      • Unsubscribe
    • Official holidays
    • Glossary
    • RSS feeds
Board of Appeals
Decisions

Recent decisions

Overview
  • 2025 decisions
  • 2024 decisions
  • 2023 decisions
  1. Home
  2. T 1712/17 (Pharmaceutical Formulations Containing Methylnaltrexone / PROGENICS) 22-09-2020
Facebook X Linkedin Email

T 1712/17 (Pharmaceutical Formulations Containing Methylnaltrexone / PROGENICS) 22-09-2020

European Case Law Identifier
ECLI:EP:BA:2020:T171217.20200922
Date of decision
22 September 2020
Case number
T 1712/17
Petition for review of
-
Application number
04759349.6
IPC class
A61K9/08
A61K45/06
A61K47/12
A61K47/18
A61K9/19
A61K31/047
A61K31/195
A61K31/485
Language of proceedings
EN
Distribution
NO DISTRIBUTION (D)

Download and more information:

Decision in EN 346.05 KB
Documentation of the appeal procedure can be found in the European Patent Register
Bibliographic information is available in:
EN
Versions
Unpublished
Application title

PHARMACEUTICAL FORMULATIONS CONTAINING METHYLNALTREXONE

Applicant name
PROGENICS PHARMACEUTICALS, INC.
Opponent name

Actavis Group PTC ehf

Fresenius Kabi Deutschland GmbH

Board
3.3.07
Headnote
-
Relevant legal provisions
Rules of procedure of the Boards of Appeal 012(4) (2007)
European Patent Convention 123(2) (2007)
European Patent Convention 084 (2007)
Rules of procedure of the Boards of Appeal 011 (2020)
Keywords

Late-filed request - request identical to request not admitted in first instance proceedings

Late-filed request - admitted (yes)

Amendments - extension beyond the content of the application as filed (no)

Remittal to the department of first instance - special reasons for remitting the case

Catchword
-
Cited decisions
T 1966/16
Citing decisions
-

I. European Patent 1615646 (hereinafter "the patent") was granted on the basis of 13 claims.

Claim 1 of the patent as granted read as follows:

"A pharmaceutical preparation comprising a solution of methylnaltrexone or a salt thereof and a chelating agent, wherein the chelating agent is ethylenediaminetetraacetic acid (EDTA) or a derivative thereof, niacinamide or a derivative thereof, or sodium desoxycholate or a derivative thereof."

II. Two oppositions were filed against the patent on the grounds that its subject-matter lacked novelty and inventive step and it extended beyond the content of the application as filed.

III. The opposition division took the decision to revoke the patent.

The decision was based on the patent as granted as main request, on auxiliary requests I and II filed by letter dated 7 July 2016, on auxiliary requests III and IV filed by letter dated 29 March 2017, and on auxiliary requests V and VI filed by letter dated 24 May 2017. The opposition division did not admit into the proceedings auxiliary request VII filed during the oral proceedings.

IV. The opposition division decided in particular as follows:

(a) The main request did not meet the requirements of Article 123(2) EPC, because claim 1 did not contain the feature that the concentration of methylnaltrexone degradation products did not exceed 2% of the methylnaltrexone or salt thereof in the preparation. Auxiliary requests I and II infringed Article 123(2) EPC for the same reason.

(b) Auxiliary request III met the requirements of Articles 123(2) and (3) EPC. However, claim 1 was found unclear for lack of information as to what the percentage of methylnaltrexone degradation products referred to. Auxiliary requests IV-VI failed to meet the requirements of clarity of Article 84 EPC for the same reason.

(c) Auxiliary request VII was filed late and did not prima facie meet the requirements of Article 123(2)EPC. Accordingly, the opposition division did not admit auxiliary request VII into the proceedings.

V. The patent proprietor (appellant) lodged an appeal against the decision of the opposition division.

With its statement setting out the grounds of appeal, the appellant defended its case on the basis of the patent as granted as main request, and on the basis of auxiliary requests I, II, III, IV, V, Va, VI, VIa, VII, VIII and IX filed therewith.

Auxiliary request VII was identical to the auxiliary request VII filed during the oral proceedings before the opposition division. It comprised a sole claim 1 reading as follows:

"A pharmaceutical preparation comprising a solution of methylnaltrexone or a salt thereof and a chelating agent, wherein the chelating agent is ethylenediaminetetraacetic acid (EDTA) or a derivative thereof, wherein the EDTA or derivative thereof is present in a concentration from 0.1 to 25.0 mg/ml, and wherein the pH is from 2.0 to 4.0."

VI. Both respondents 1 (opponent 1) and 2 (opponent 2) replied to the appeal.

VII. In a communication under Article 15(1) RPBA, the Board expressed its preliminary opinion.

VIII. Oral proceedings were held before the Board in the presence of the appellant only. Neither respondent 1 nor respondent 2 attended the oral proceedings, as announced respectively in their letters dated 18 September 2019 and 4 May 2020.

In the course of the oral proceedings, the appellant made auxiliary request VII its main request.

IX. The appellant's arguments as regards auxiliary request VII (now pursued as the main request) can be summarised as follows:

(a) The conclusion of the opposition division according to which auxiliary request VII did not prima facie overcome the objections under Article 123(2) EPC was not correct (see (b) below). Hence auxiliary request VII should be admitted into the proceedings.

(b) Auxiliary request VII found basis, for the purposes of Article 123(2) EPC, in claims 1, 11, 12 and 23 of the application as filed, as well as page 2, lines 16-18. Claim 1 of the main request did not contain the feature that the concentration of methylnaltrexone degradation products did not exceed 2% of the methylnaltrexone or salt thereof in the preparation. However this feature was made redundant by the limitation to a pH of 2.0 to 4.0 and to an amount of EDTA or derivative thereof of 0.1 to 25.0 mg/ml, as taught in the description of the application as filed, page 12 lines 14-15 and 30-32, and page 13, line 28 to page 14, line 15. Hence the feature regarding a concentration of methylnaltrexone degradation products of at most 2% could be dispensed with.

Alternatively, auxiliary request VII found basis in the last paragraph on page 3 of the application as filed, in combination with page 6, lines 4-6, page 14, lines 11-15, and page 2, lines 9-12 for the chelating agent; page 2 and claims 11-12 for the EDTA concentration; page 3, lines 30-31 and claim 23 for the pH range.

X. The respondents' arguments as regards auxiliary request VII can be summarised as follows:

(a) Auxiliary request VII should not be admitted into the proceedings. The opposition division had exercised its discretion in an appropriate way, by finding that auxiliary request VII did not meet the requirements of Article 123(2) EPC (see (b) below). The Board should therefore not overrule the way in which the opposition division had exercised its discretion.

(b) The subject-matter of auxiliary request VII was not disclosed on page 3 of the application as filed. Said passage on page 3, lines 18-26 defined a solution of methylnaltrexone in a degradation inhibiting agent, and not a preparation comprising a solution of methylnaltrexone or salt thereof and a chelating agent as in auxiliary request VII.

Furthermore, said passage of the application as originally filed contained further features such as the amount of degradation inhibiting agent, the stability of the composition or its processing under at least one sterilisation technique, which were missing from auxiliary request VII.

Lastly, the preparation of auxiliary request VII covered embodiments in which the pH and/or the EDTA concentration were not sufficient to provide a low amount of methylnaltrexone degradation products after autoclaving.

Claims 11 and 12 could not function as pointers for the claimed EDTA concentration, as they were dependent on claim 1 which also contained the stability criteria regarding the amount of methylnaltrexone degradation products, in accordance with the aspect described on page 2. Similarly, claim 23 of the application as originally filed was not a pointer for the claimed pH range, as it was also dependent on claim 1. The stability criteria of claim 1 could not be omitted without infringing Article 123(2) EPC.

Accordingly, auxiliary request VII did not meet the requirements of Art 123(2) EPC.

XI. The following requests are relevant to this decision:

The appellant requests that the decision under appeal be set aside and that the case be remitted to the opposition division for further prosecution on the basis of auxiliary request VII filed with the statement setting out the grounds of appeal.

Respondents 1 and 2 request that the appeal be dismissed. Respondent 1 further requests that auxiliary request VII not be admitted into the proceedings.

Auxiliary request VII (pursued as the main request)

1. Admittance into the proceedings

The appellant submitted auxiliary request VII together with its statement setting out the grounds of appeal, which was filed before 1 January 2020. Following the transitional provisions set out in Article 25(2) RPBA 2020, the admittance of auxiliary request VII must be decided on the basis of Article 12(4) RPBA 2007. Article 12(4) RPBA 2007 gives the Board discretion not to admit, on appeal, requests which could have been presented or were not admitted in the first instance proceedings.

1.1 Auxiliary request VII was filed during the oral proceedings in opposition. The opposition division did not admit auxiliary request VII into the proceedings. Nonetheless, the Board retains its own margin of discretion to admit auxiliary request VII upon appeal, pursuant to Article 12(4) RPBA 2007.

1.2 Auxiliary request VII is aimed at overcoming the opposition division's finding that auxiliary requests III-VI did not comply with the requirements of Article 84 EPC. As noted by the appellant, in the course of the proceedings before the opposition division, the clarity objection was raised for the first time during the oral proceedings. In these circumstances, the Board sees the filing of auxiliary request VII as justified by the developments in the first-instance proceedings.

Accordingly, auxiliary request VII is admitted into the proceedings.

2. Article 123(2) EPC

2.1 As basis for claim 1 of auxiliary request VII, the appellant cites among others claims 1, 11, 12 and 23 of the application as filed.

The Board notes that claim 1 of auxiliary request VII differs from claim 1 of the application as filed by the addition of the features pertaining to

- the presence of a chelating agent being EDTA or a derivative thereof,

- the concentration range of from 0.1 to 25.0 mg/ml for said EDTA or derivative thereof, and

- the pH range of from 2.0 to 4.0,

and by the deletion of the feature "wherein the preparation after autoclaving has a concentration of methylnaltrexone degradation products that does not exceed 2% of the methylnaltrexone or salt thereof in the preparation".

2.2 The Board considers that both the presence of EDTA or derivative thereof as chelating agent and its concentration range of from 0.1 to 25.0 mg/ml find basis in claims 11 and 12 of the application as filed. The presence of EDTA or derivative thereof as chelating agent is required by claims 11-12, and by claims 7 and 8 on which they depend. In addition, claim 11 discloses a broad concentration range of 0.05 to 25.0 mg/ml for EDTA or its derivative, whereas claim 12 discloses a more preferred range of 0.1 to 2.5 mg/ml. According to established case law, in the case of such a disclosure of both a general and a preferred range, a combination of the preferred disclosed narrower range and one of the part-ranges lying within the disclosed overall range on either side of the narrower range is unequivocally derivable from the original disclosure of the patent in suit and thus supported by it (see Case Law of the Boards of Appeal, 9th edition, July 2019, II.E.1.5.1). The concentration range of 0.1 to 25.0 mg/ml of auxiliary request VII is thus derived directly and unambiguously from claims 11 and 12.

Furthermore, the pH range of 2.0 to 4.0 is disclosed in dependent claim 23, or, alternatively, on page 2, lines 16-18.

2.3 Claim 1 of auxiliary request VII omits the feature of claim 1 of the application as filed according to which "the preparation after autoclaving has a concentration of methylnaltrexone degradation products that does not exceed 2% of the methylnaltrexone or salt thereof in the preparation". The Board however agrees with the appellant that, in view of the teaching of the application as filed, this feature is made redundant by the limitations pertaining to the pH of 2.0 to 4.0 and the concentration range of from 0.1 to 25.0 mg/ml for the EDTA or derivative thereof, for the following reasons.

2.3.1 Regarding the pH, the application as filed on page 12, lines 14-15 and 30-32 indicates that "pH alone can solve the problem of excessive methylnaltrexone degradation products" and teaches the effect of a pH below 4.25 (thus encompassing the claimed range of 2.0-4.0) on the amount of methylnaltrexone degradation products following autoclaving.

2.3.2 As to the choice and amount of EDTA or derivatives thereof as chelating agent, page 13, lines 28-29, indicates that "a chelating agent alone was capable of reducing the amount of degradation product to acceptable levels". In the same paragraph, disodium edetate is said to stabilize methylnaltrexone against heat degradation in a concentration-dependent manner, and a concentration of 0.1 mg/ml already results in under 1.5% (hence less than 2%) total degradants (page 14, line 2). This result is generalised to EDTA and derivatives in the following paragraph (page 14, line 13).

2.3.3 Consequently, it is directly and unambiguously derivable from the application as filed as a whole that the selection of the claimed pH range and concentration range for EDTA or derivatives leads to a concentration of methylnaltrexone degradation products that does not exceed 2%. This teaching is not contradicted by any passage of the application as filed. In particular, the conditions under which more than 2% degradants were observed (i.e. a pH between 6.0 and 7.0, cf. page 14 lines 25-28; or a concentration of 0.01 mg/ml of sodium edetate, cf. page 14, line 1) are not covered by claim 1 of auxiliary request VII.

Respondent 1 expressed the view that the preparation claimed in auxiliary request VII covered embodiments in which the pH and/or the EDTA concentration were not sufficient to provide a low amount of methylnaltrexone degradation products after autoclaving. However, the application as filed does not disclose such embodiments. The Board stresses that, for the purposes of Article 123(2) EPC, the relevant question is whether the application as filed teaches that the features of the amended claim lead to the fulfillment of the omitted feature (that is the feature pertaining to the concentration of methylnaltrexone degradation products that does not exceed 2% after autoclaving). The question is not whether this teaching is verified by facts.

Therefore, the omission of the feature relating to the methylnaltrexone degradation products that does not exceed 2% satisfies the "gold standard", and remains within the limits of what the skilled person would regard as directly and unambiguously derivable from the application as filed.

2.4 The appealed decision found the subject-matter of auxiliary request VII to result from multiple selections. Although this reasoning was based on different passages of the application as filed (namely page 3), the Board emphasizes that the application as filed provides support for the combination of the above features.

Thus, the opposition division considered that the presence of EDTA or derivative thereof as chelating agent resulted from several selections, namely the selection of a chelating agent out of the possible methylnaltrexone degradation inhibiting agents, and the selection of EDTA or derivative thereof from the list of chelating agents. The Board does not agree. The choice of EDTA or derivative thereof necessarily entails the presence of this chelating agent in the preparation. Hence this feature does not involve multiple selections within two independent lists of alternative features.

Furthermore, the passages of the application as filed discussed above (see 2.3.1 and 2.3.2), which emphasize the effect of the selected pH range, chelating agent and amount thereof on the extent of degradation of methylnaltrexone, can be seen as pointers to the combination of these features.

2.5 In conclusion, auxiliary request VII meets the requirements of Article 123(2) EPC.

3. Clarity

The respondents did not raise any objection regarding the clarity of auxiliary request VII. The Board considers that the amendments do not introduce any non-compliance with Article 84 EPC.

4. Remittal to the opposition division

Under Article 11 RPBA 2020 the board may remit the case to the department whose decision was appealed if there are special reasons for doing so. In the present case, the opposition division decided only on the question of added subject-matter and clarity. There is no appealable decision regarding the further grounds for opposition under Article 100(a) EPC. In these circumstances, the Board considers that special reasons for remitting the case to the opposition division exist (see T 1966/16, point 2). Therefore, the Board considers it appropriate to accede to the appellant's request for a remittal.

Order

For these reasons it is decided that:

The decision under appeal is set aside.

The case is remitted to the opposition division for further prosecution.

Footer - Service & support
  • Service & support
    • Website updates
    • Availability of online services
    • FAQ
    • Publications
    • Procedural communications
    • Contact us
    • Subscription centre
    • Official holidays
    • Glossary
Footer - More links
  • Jobs & careers
  • Press centre
  • Single Access Portal
  • Procurement
  • Boards of Appeal
Facebook
European Patent Office
EPO Jobs
Instagram
EuropeanPatentOffice
Linkedin
European Patent Office
EPO Jobs
EPO Procurement
X (formerly Twitter)
EPOorg
EPOjobs
Youtube
TheEPO
Footer
  • Legal notice
  • Terms of use
  • Data protection and privacy
  • Accessibility